BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...
TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...